Heartflow received nationwide UnitedHealthcare coverage for its AI CT plaque analysis software and announced plans for a $200M IPO at a $1.3B valuation.
Key Details
- 1UnitedHealthcare will provide nationwide coverage for Heartflow's CT-based plaque analysis software, effective October 1.
- 2Coverage applies to all UnitedHealthcare plans, including commercial, Medicare Advantage, and dual-eligible offerings.
- 3Heartflow aims to raise up to $212.5 million by offering 12.5 million shares at $15–$17 per share in its IPO.
- 4Company generated about $43 million in Q2 2025, up 40% year-over-year.
- 5Heartflow's platform has assessed over 400,000 patients for coronary artery disease as of March 31, 2025.
- 6The US market opportunity for Heartflow's products is estimated at $5 billion.
Why It Matters
Nationwide insurer coverage and a strong IPO position solidify Heartflow's AI solution as a standard in coronary CT interpretation. This represents a significant step in the adoption and reimbursement of radiology AI, paving the way for broader clinical and commercial implementation.
Source
Radiology Business
Related News
•Radiology Business
Lucida Medical Raises $11M for AI-Based Prostate MRI Diagnosis Expansion
Lucida Medical, specializing in AI-assisted prostate cancer diagnosis via MRI, raises $11.4M to drive US FDA approval and platform expansion.
•Radiology Business
NYC Health + Hospitals CEO Considers AI to Replace Radiologists
NYC Health + Hospitals CEO suggests AI could partially replace radiologists, pending regulatory approval.
•AuntMinnie
AI Mammography Tool Shows No Significant Benefit in Single-Reader U.S. Study
A real-world study found no significant improvement in breast cancer detection or recall rates with an FDA-approved AI mammography tool in a single-reader setting.